ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > CD4

CD4

概要

Name:T-cell surface antigen CD4
Target Synonym:CD4mut,CD4 Antigens,T-cell surface antigen T4/Leu-3,T-cell surface glycoprotein CD4,CD4,CD4 Molecule,CD4 Antigen (P55),CD4 Receptor,CD4 Antigen
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:23
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

ACRO Quality

生物活性データの一部

FABm002-04-Cell-based assay
 CD4 FACS

Flow cytometric analysis of Human peripheral blood lymphocytes respectively staining with PE-CY7-Labeled Anti-Human CD4 Antibody Mouse IgG1(Cat. No. FABm002-01) at 1:20 dilution (5 μL of the antibody stock solution corresponds to labeling of 2.5e5 cells in a final volume of 100 µL), compared with isotype control antibody. PE-CY7 signal was used to evaluate the binding activity (QC tested).

CD4-HP2E3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-CD4 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD4, His Tag (Cat. No. CD4-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

CD4-HF2H7-ELISA
 CD4 ELISA

Immobilized Ibalizumab at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human CD4, His Tag (Cat. No. CD4-HF2H7) with a linear range of 0.01-0.156 μg/mL (QC tested).

CD4-R82E3-MALS-HPLC
CD4 MALS images

The purity of Biotinylated Rhesus macaque CD4,His,Avitag (Cat. No. CD4-R82E3) is more than 90% and the molecular weight of this protein is around 43-53 kDa verified by SEC-MALS.

Synonym Name

CD4,CD4mut,LEU3

Background

Cluster of Differentiation 4 (CD4) is also known as T-cell surface antigen T4/Leu-3 (LEU-3) and CD4mut, is a single-pass type I  membrane glycoprotein,and is a member of the immunoglobulin superfamily. CD4 expressed on the surface of T helper cells, monocytes, macrophages, and dendritic cells. It has four immunoglobulin domains (D1 to D4) that are exposed on the extracellular surface of the cell: D1 and D3 resemble immunoglobulin variable (IgV) domains. D2 and D4 resemble immunoglobulin constant (IgC) domains. CD4 is a co-receptor that assists the T cell receptor (TCR) with an antigen-presenting cell. Using its portion that resides inside the T cell, CD4 amplifies the signal generated by the TCR by recruiting an enzyme, known as the tyrosine kinase lck, which is essential for activating many molecules involved in the signaling cascade of an activated T cell. CD4 also interacts directly with MHC class II molecules on the surface of the antigen-presenting cell using its extracellular domain. The extracellular domain adopts an immunoglobulin-like beta-sandwich with seven strands in 2 beta sheets, in a Greek key topology. CD4 has also been shown to interact with SPG21, Lck and Protein unc-119 homolog. CD4 is a primary receptor used by HIV-1 to gain entry into host T cells. HIV infection leads to a progressive reduction of the number of T cells possessing CD4 receptors. Therefore, medical professionals refer to the CD4 count to decide when to begin treatment for HIV-infected patients.

Clinical and Translational Updates

相関分子

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ibalizumab Hu5A8; TMB-355; TNX-355; 5AB Approved Biogen Inc 特罗格佐, Trogarzo EU HIV Infections Theratechnologies Europe Ltd 2018-03-06 HIV Infections Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
CALRLong36 peptide (Herlev Hospital) Phase 1 Clinical Herlev Hospital Myeloproliferative Disorders Details
CD4^LVFOXP3 Treg-like cell therapy CD4^LVFOXP3 Phase 1 Clinical Stanford University Polyendocrinopathies, Autoimmune Details
TMB-365 TMB-365 Taimed Biologics Inc Details
SCRI-E2CAR_EGFRtv1 SCRI-E2CAR_EGFRtv1 Umoja BioPharma Inc Details
IMCY-0141 IMCY-0141 Imcyse Sa Details
Anti-CD4 CAR T-cell therapy (University of Pennsylvania) CAR-C34ZFN University Of Pennsylvania Details
RB-0003 RB-0003; BNT-111 Biontech Se, Tron Details
Tregalizumab hB-F5; BT-061 Phase 2 Clinical Biotest Pharma Gmbh Drug Hypersensitivity; Arthritis, Rheumatoid; Psoriasis; Asthma Details
Mosedipimod EC-18 Phase 2 Clinical Enzychem Lifesciences Co Neutropenia; Coronavirus Disease 2019 (COVID-19); Stomatitis; Febrile Neutropenia Details
IT-1208 (Kyowa Hakko Kirin) IT-1208 Phase 1 Clinical Kyowa Hakko Kirin Co Ltd Neoplasms Details
GEN-009 GEN-009 Phase 2 Clinical Genocea Biosciences Inc Skin Melanoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung Details
VRC-07-523 VRC-07-523-L S; VRC-HIVMAB075-00-AB; VRC-HIVMAB-075 -00-AB; VRC-07-523; TMB-380 Phase 2 Clinical National Institute Of Allergy And Infectious Diseases (Niaid), Taimed Biologics Inc HIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral Details
VRC-01-LS VRC-HIVMAB-080-00-AB; VRC-01-LS Phase 2 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) HIV Infections Details
10E8.4/iMab (Aaron Diamond AIDS Research Center) TMB-370 Phase 1 Clinical Aaron Diamond Aids Research Center For The City Of New York, Inc HIV Infections Details
T-allo-10 T-allo-10 Phase 1 Clinical Stanford University Hematologic Diseases; Graft vs Host Disease Details
CD4 CAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Lymphoma, T-Cell Details
CD4-directed chimeric antigen receptor engineered T-cells (Icell Gene) CD4CAR (Icell Gene) Phase 1 Clinical Stony Brook University School Of Medicine, Icell Gene Therapeutics (Int'L) Ltd, University Of Louisville Lymphoma, T-Cell; Leukemia, T-Cell Details
Autologous Regulatory Т-cell Therapy Phase 2 Clinical Institute Of Biophysics And Cell Engineering Of National Academy Of Sciences Of Belarus Scleroderma, Systemic Details
VRC-HIVMAB091-00-AB N6LS; Z258‐N6LS; VRC-HIVMAB091-00-AB Phase 2 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) HIV Infections Details
LB-1901 LB-1901; LB1901 Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd Lymphoma, T-Cell, Peripheral; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous Details
VRC-HIVMAB0115-00-AB Phase 1 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) HIV Infections Details
Semzuvolimab dB4; UB-421; mAb-B4 Phase 3 Clinical United Biomedical Inc HIV Infections Details
ITV 1(Nonindustrial source) ITV-1 Phase 3 Clinical Synexa Life Sciences, Immunotech Laboratories, Nonindustrial Source HIV Infections Details

This web search service is supported by Google Inc.

totopphone